02348 DAWNRAYS PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 4.64X | Oper Margin | 20.3% |
|---|---|---|---|
| LT Debt/Equity | N/A | Net Margin | 17.4% |
| Total Debt/Equity | 2.3% | Return on Equity | 6.3% |
| Price/Book | 0.46X | Return on Assets | 5.3% |
| (HKD 1.160) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 238.17 | 600.81 | 359.32 | 401.45 | 438.08 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | -60.4 | +67.2 | -10.5 | -8.4 | +37.7 |
| Earnings Per Share (HKD) | 0.159 | 0.399 | 0.24 | 0.268 | 0.293 |
| Earnings Per Share Growth (%) | -60.3 | +66.6 | -10.6 | -8.4 | +42.0 |
| Dividend Per Share (HKD) | 0.063 | 0.095 | 0.080 | 0.088 | 0.080 |
| P/E* (X) | 7.32 | 2.91 | 4.84 | 4.33 | 3.97 |
| Yield (%) | 5.43 | 8.19 | 6.90 | 7.59 | 6.90 |
| Dividend Share (%) | 39.75 | 23.80 | 33.39 | 32.85 | 27.35 |
| Book NAV (HKD) | 2.506 | 2.354 | 2.097 | 1.976 | 1.943 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 1,231 | 1,060 | +16.1 | 1,151 |
| Operating Result | 249.613 | 353.975 | -29.5 | 454.99 |
| Associates | 0 | -3.696 | -100.0 | -40.933 |
| Profit Before Taxation | 249.613 | 636.949 | -60.8 | 414.057 |
| Taxation | 38.506 | 74.187 | -48.1 | 91.39 |
| Profit /( Loss) After Taxation | 211.107 | 562.762 | -62.5 | 322.667 |
| Minority Interests | -2.864 | -2.178 | +31.5 | -3.333 |
| Net Profit | 213.971 | 564.94 | -62.1 | 326 |
| Earnings Per Share () | 0.1585 | 0.3992 | -60.3 | 0.2396 |
| Dividend Per Share () | 0.0630 | 0.0950 | -33.7 | 0.0800 |
| Announcement Date | 2026-03-27 | 2025-03-28 | NA | 2024-03-22 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
